FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Investors | Eli Lilly and Company
- FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity Investors | Eli Lilly and Company
- F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea The New York Times
- Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea Reuters
- FDA approves weight-loss drug Zepbound for obstructive sleep apnea CNN
- FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. CNBC